AI Article Synopsis
- The introduction of vaccines has raised hope in fighting SARS-CoV-2, but viral variants and lack of strong antivirals create ongoing challenges.
- The study highlighted that individuals who recovered from COVID-19 showed a quick immune response, while those who didn't survive had slower and weaker antibody development, especially with S2 antibodies.
- The research suggests that having pre-existing immunity from other coronaviruses, like OC43, may help enhance the immune response in those who survive or have mild COVID-19 symptoms.
Article Abstract
The introduction of vaccines has inspired new hope in the battle against SARS-CoV-2. However, the emergence of viral variants, in the absence of potent antivirals, has left the world struggling with the uncertain nature of this disease. Antibodies currently represent the strongest correlate of immunity against COVID-19, thus we profiled the earliest humoral signatures in a large cohort of severe and asymptomatic COVID-19 individuals. While a SARS-CoV-2-specific immune response evolved rapidly in survivors of COVID-19, non-survivors exhibited blunted and delayed humoral immune evolution, particularly with respect to S2-specific antibody evolution. Given the conservation of S2 across β-coronaviruses, we found the early development of SARS-CoV-2-specific immunity occurred in tandem with pre-existing common β-coronavirus OC43 humoral immunity in survivors, which was selectively also expanded in individuals that develop paucisymptomatic infection. These data point to the importance of cross-coronavirus immunity as a correlate of protection against COVID-19.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132219 | PMC |
| http://dx.doi.org/10.1101/2021.05.11.443609 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The survival of B cells is compromised in kidney disease.
Nat Commun
December 2024
Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Antibody-mediated protection against pathogens is crucial to a healthy life. However, the recent SARS-CoV-2 pandemic has shown that pre-existing comorbid conditions including kidney disease account for compromised humoral immunity to infections. Individuals with kidney disease are not only susceptible to infections but also exhibit poor vaccine-induced antibody response.
View Article and Find Full Text PDFSafety and durability of the immune response after vaccination with the heterologous schedule of anti-COVID-19 vaccines SOBERANA®02 and SOBERANA® Plus in children 3-18 years old.
Vaccine X
January 2025
Finlay Vaccine Institute, Av. 21 #19810, Atabey, Playa, Havana 11600, Cuba.
Background: The heterologous three-dose schedule of the protein subunit anti-COVID-19 SOBERANA®02 and SOBERANA® Plus vaccines has proved its safety, immunogenicity and efficacy in pediatric population, but durability of immunogenicity is not yet dilucidated. This study reports the safety and durability of the humoral and cellular responses in children and adolescents 5-7 months after receiving the heterologous vaccine schedule of SOBERANA® 02 and SOBERANA® Plus.
Methods: Children participating in a phase I/II clinical trial were followed-up for 5-7 months after the last dose.
[B cells in chronic hepatitis: advances and mechanistic].
Zhonghua Gan Zang Bing Za Zhi
December 2024
Senior Department of Infection Disease, the Fifth Medical Center of PLA General Hospital, Beijing100039, China.
The article reviews the role and functional diversity of B cells in chronic hepatitis B (CHB). B cells play a crucial role in humoral immunity, participating in the clearance of hepatitis B virus (HBV) through antibody production, antigen presentation, and immune regulation. In HBV infection, B cells exhibit antigenic heterogeneity, with immune responses to different HBV antigens varying.
View Article and Find Full Text PDFMALT1 promotes the antibacterial immune response by activating NF-κB signaling and enhancing hemocyte phagocytosis in the Chinese mitten crab.
Fish Shellfish Immunol
December 2024
School of Aquatic and Life Sciences, Shanghai Ocean University, Shanghai, China. Electronic address:
Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), a scaffold protein, plays a pivotal role in the NF-κB pathway downstream of T-cell receptors (TCRs) and B-cell receptors (BCRs). As a key signaling hub, MALT1 integrates various pathways, making it essential for both innate and adaptive immunity. However, its role in the antibacterial immune responses of crustaceans remains unclear.
View Article and Find Full Text PDFControlling vaccine kinetics using tannic acid for enhanced humoral immunity.
J Control Release
December 2024
John A Paulson School of Engineering & Applied Sciences, Allston, MA 02134, USA; Wyss Institute of Biologically Inspired Engineering, Boston, MA 02215, USA. Electronic address:
Despite the success of global vaccination campaigns, vaccine access in low-resource settings is an ongoing challenge. Subunit vaccines are a well-established and clinically scalable intervention, yet they have achieved limited success for poorly immunogenic antigens such as those associated with SARS-CoV-2. Delivery strategies that promote gradual release of subunit vaccines from the injection site offer the potential to improve humoral immunity by enhancing lymph node exposure, however, clinical implementation of this strategy is challenging due to poor scalability and high costs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!